SEHK:2142Biotechs
Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?
HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors.
See our latest analysis for HBM Holdings.
The HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...